Member Info for Bmhltd

Https://www.linkedin.com/posts/faron_we-are-pleased-to-welcome-erika-johnson-froneberg-activity-7455520780982861824-gK3n?utm_medium=ios_app&rcm=ACoAADM1xY8BPFp_YBv8stSQEZalLsa87LNQA40&utm_source=social_share_send&utm_campaign=copy_link

Howard,

I think it’s largely because the CR rate is nearly treble what is usually expected with standard of care Azacitidine alone. The FDA’s new guidance allows for approval on this endpoint as long as they are clinically meaningful responses and not detrimental to overall survival which means there is scope here for a new all-comer standard of care in a highly valuable Hemo indication which hasn’t seen progress in decades.

Just touched 10% up from the Rights issue price in Finland. Sure beats it going the other way.

GLA

Just received from Paavo:

UK custodians and brokers have received all the necessary instructions to create the required corporate actions on their side. As each broker may follow its own internal process and timelines, we are actively following up them to proceed accordingly.

Thank you for pointing this out.

Best,

Paavo

* I still this morning haven’t heard anything and have phoned my broker multiple times also.

Places us at a disadvantage as Finnish brokers have been trading their rights since yesterday.

I’ve emailed Faron this morning and will report back if I hear anything…

Hopefully some nice uptake on the directed issue to take care of part / all of the CLN would be great news to take the shackles off the stock price also…

Cheers both.

JR- my take is following the RI we will be cashed up to meet our objectives. A pushing out of the timeline from where we were previously believed to be, but randomised data in the Front Line population and the approval pathways for both fl and r/r populations should be known within this funding round window, hopefully on response rate readout, and should put us in a strong position following a successful readout with further indications for a platform valuation if the IIT trials start hitting too.

It’s a cheap place to get further cash exposure if you believe in Bexmarilimab.

€100m market cap with over a third of that in cash feels very cheap if you can wait things out. A rerate could be much quicker but I am just viewing it as a postponement of a major valuation uplift, all being well with the upcoming trials which should be much quicker to materialise and cheaper given CR endpoint.

Has anyone’s broker issued a notification for the Rights Issue Corporate action yet?

Cheers

If you take up your rights, you aren’t diluted, and have an almost identical share of the whole company.

The company then also has a much greater cash position, but a perhaps further away than expected major inflection point.

Saying this, the new approach seems a much more sensible and more careful way of taking things forward than was previously communicated ie an all-or-nothing seamless phase 2/3.

The RR readout should be much faster to achieve, much cheaper and the options for AA approvals in either the r/r and/or fl population become a real possibility and / or the randomised data that could lead to a deal / buyout.

I’m chalking this up as a push back in near term major uplift in valuation and as a very cheap price to get further cash exposure to the end points suggested above…

80 million shares approved to be allotted.

Should get the RI issue deets soon…

From the initial RNS it says it expects it to complete by end of Q1 so I think it unlikely tbh. Things will likely move fast after the EGM

Greenman DK, call your broker, once they have the details of the rights issue which should be by mid next week, ask them to put your rights into a dealing account. That way you should be able to take up your rights in that account if you don’t have cash allowance available left In your ISA accounts.

Mine offers this service. But you will need to contact them before the stock goes ex-rights, and the rights detach from the stock.

why would you not announce the news of this first given it is a clear value inflection point sooner and cheaper.

maybe they want to flush out the cln short, let them close out, and soon they will announce the cln is now a holder rather than a cln.

crazy ****.

glad i didn’t sell, but seems like a ****ed up way of going about things…

I’ve actually added a few on the Helsinki exchange this morning.

We wait now for tomorrow’s update from Juho, the EGM early March annd clarity on price and Structure of the raise and focusing on the broader pipeline, while awaiting any deal making that may or may not come in the near future…

I’ll be off here for a little while. Good luck all…

Very unlikely to be that low in my opinion junior, they will have headroom and this is just for optionality.

My take is there is more intrinsic value in the company by getting to the next milestones.

Like Sax says, it doesn’t preclude deals, it actually increases the chances, as a company that is capitalised to reach key milestones is more attractive to suitors.

It’s not ideal, but for long termers it’s the best course of action…, if a fair deal wasn’t on the table…

The price will likely be determined after the EGM in early March Sax. This is the fairest way a raise can be done for existing holders and you will be able to sell your rights most likely.

It’s likely to be volatile in the mean time, but selling early is unlikely to be the smartest move, imo.

Regarding solid tumours, if early data in blaze hints at a switch back to M1 macrophages and the TME is re-sensitised to ICI’s, perhaps even enhanced given bexmab study, and our understanding of secreted clever-1, I do not see how Gilead are not compelled to go into full acquisition mode and take the whole company.

A safer and more efficacious version of Magrolimab with strong data in MDS and emerging data in NSCLC melanoma and a pipeline of STS and breast cancer coming online becomes too valuable to ignore for a major like Gilead, looking to enhance Zimberlimabs scope and take on blood cancers, with a highly efficient tax environment with regard to R&D expenses.

Of course there are several ways this could still play out and we wait for the next update.

Would love it if the new CFO deems it appropriate to pay February’s CLN in cash. That would signal some strong confidence and give us breathing space to finish off whatever deal is being worked on for another couple of months.

Feels as though shares are becoming more tightly held lately and perhaps weaker hands have been shaken out so could be a very smart move.

Either way, not worth selling as Bex will generate billions per annum for the owner in the next few years. We only need cash to get the first 120 patients done, and early solid tumour combo data before we will be the “belle of the ball.”

Not sure it can be that hard to replace the CLN with a cornerstone investor and get another 25 million to get us comfortably to that point if we remain fully independent until then.

Even at 2.50 eur a share, 20m shares would be €50m and be enough to take us to the promised land.

AIMO.

I guess they will have a big bounty of cash to shop elsewhere on their BD initiatives now……..

https://breakingthenews.net/Article/Merck-said-to-end-talks-to-buy-Revolution-Medicines/65538467

1250 shares